AbCellera Biologics Inc. ABCL Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11)?
- AbCellera Biologics Inc. (ABCL) reported accounts payable and other current liabilities (note 11) of $20.81M in Q1 2026.
- How has AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11) changed year-over-year?
- AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11) decreased by 36.6% year-over-year, from $32.8M to $20.81M.
- What is the long-term trend for AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11)?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s accounts payable and other current liabilities (note 11) has grown at a 19.4% compound annual growth rate (CAGR), from $14.83M to $25.23M.